Additional clinical, regulatory and commercialization milestone payments
Arcus Biosciences·Products & Services·1 segment
Breakdown
Segments
anti-CD39View metric
| Segment | Q1 '23 | Q1 '24 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|
| anti-CD39 | $14M | $14M | $14M | $14M |
| Total | $14M | $14M | $14M | $14M |